ID
45412
Descrição
Principal Investigator: Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000548 The study protocol for both cohorts has been previously described (Journal of Thrombosis and Thrombolysis 2012:1-12). HV1 cohort: Briefly 50 healthy volunteers were exposed to two weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by microarray before and after aspirin exposure. The pre-aspirin samples were profiled on the U133A 2.0 array and the post-aspirin samples were profiled on the U1333plus 2.0 array. HV2 cohort: Briefly 53 healthy volunteers were exposed to four weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by U133plus 2.0 array before and after aspirin exposure.
Link
Palavras-chave
Versões (1)
- 20/11/2022 20/11/2022 - Chiara Middel
Titular dos direitos
Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA
Transferido a
20 de novembro de 2022
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs000548 Aspirin Pharmacogenomics
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
C0680251 (UMLS CUI [1,2])
C1552738 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])